Clinical trials: HIV Positive
Contraception, HIV
Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics
The project is a two-arm prospective cohort and pharmacokinetic study comparing levonorgestrel and ethinyl estradiol pharmacokinetics in HIV-positive women taking antiretroviral regimens that include ritonavir to those in women…
- Trial name
- NCT02531321
- Testing
- Levonorgestrel and Ethinyl Estradiol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Southern California
Tuberculosis, Healthy
Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.
The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential substitute for BCG vaccination. BCG vaccination has indeed demonstrated its major limitation in inducing protection against tuberculosis…
- Trial name
- MTBVAC (NCT02013245)
- Testing
- MTBVAC live vaccine, Commercially available BCG live vaccine
- Where
- Switzerland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biofabri, S.L
Opioid Dependence, Addiction
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
The purpose of this study is to conduct empiric studies of tuberculosis (TB) among people in prison with and without a history of opioid dependence.
- Conditions
- Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis
- Trial name
- HARAPAN II (NCT03089983)
- Testing
- Isoniazid, Rifapentine
- Where
- Malaysia
- Volunteers
- 316 people
- Sponsor
- Yale University
Latent Tuberculosis, Human Immunodeficiency Virus
Doravirine, Rifapentine and Isoniazid Interaction
Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex.
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Trial name
- DORIIS (NCT03886701)
- Testing
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Walter K. Kraft
Tobacco Use Cessation
Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts
The overall goal of this research project is to examine the feasibility, acceptability, and preliminary efficacy of nicotine replacement therapy preloading (NRT-P) in HIV-positive smokers, who are struggling with cigarette…
- Trial name
- NCT04994444
- Testing
- Nicoderm CQ 21Mg/24Hr Transdermal System
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV Positive, Malnourished
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
Children living with HIV from sub-Saharan Africa often present with severe malnutrition. In severe malnutrition, metabolic and/or gut structural derangement may lead to inadequate antiretroviral (ARV) absorption and/or erratic…
- Trial name
- NCT01818258
- Testing
- ZDV+3TC+LPV/r
- Where
- 5 sites in Malawi, Tanzania and 2 more
- Volunteers
- 52 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Antibody Positivity
Feasibility of Positive Links for Youth Care Engagement Intervention
A small pilot study to assess feasibility and acceptability of the PL4Y intervention.
- Trial name
- NCT05689515
- Testing
- Mobile health app
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
HIV Enteropathy, Diarrhea With HIV
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.
- Trial name
- NCT01374490
- Testing
- Crofelemer
- Where
- 21 sites in United States
- Volunteers
- 250 people
- Sponsor
- Bausch Health Americas, Inc.
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers.
- Conditions
- Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04083170
- Testing
- Fludarabine, Cyclophosphamide, Thiotepa
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV/AIDS, Clinical Depression
Zaleplon in HIV Patients With Depression
In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index…
- Trial name
- NCT03489304
- Testing
- Zaleplon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
HIV, HIV Infections
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing…
- Trial name
- NCT01815736
- Testing
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF
- Where
- 167 sites in United States, Australia and 18 more
- Volunteers
- 1,443 people
- Sponsor
- Gilead Sciences
Staphylococcus Aureus, HIV Infections
Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
DESIGN: This single center, double-blinded, randomized phase II study is being conducted to assess the efficacy of a rifabutin based regimen to eliminate S. aureus colonization in HIV infected individuals.
- Trial name
- NCT00869518
- Testing
- rifabutin plus trimethoprim sulfamethoxazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Tuberculosis
Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed.
- Trial name
- NCT00082173
- Testing
- Moxifloxacin
- Where
- Brazil
- Volunteers
- 170 people
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus
Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults
This is a Phase IV, open label, observational study to compare the gastrointestinal tissue concentrations, inflammatory response, and viral replication of two integrase-inhibitors, raltegravir and dolutegravir, in HIV-infected…
- Trial name
- NCT02218320
- Testing
- Raltegravir, Dolutegravir, Colonoscopy with biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of…
- Trial name
- PNEU-WAY (NCT03480802)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis, Latent Tuberculosis
Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
The Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial) study will be a three-arm, open-label, parallel, randomized trial.
- Conditions
- Tuberculosis, Latent Tuberculosis, HIV/AIDS
- Trial name
- NCT03934931
- Testing
- Streamlined weekly DOT visits, Weekly DOT visit reminders, Cost reimbursement DOT
- Where
- Uganda
- Volunteers
- 1,656 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Group B Streptococcal Infection
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
A randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women…
- Trial name
- NCT04596878
- Testing
- GBS-NN/NN2
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Tuberculosis
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed…
- Trial name
- NCT02465216
- Testing
- ID93 + GLA-SE
- Where
- 3 sites in South Africa
- Volunteers
- 60 people
- Sponsor
- Access to Advanced Health Institute (AAHI)